Cargando…
Potential Therapeutic Role of HDAC Inhibitors in FUS-ALS
Mutations in the FUS gene cause amyotrophic lateral sclerosis (ALS-FUS). However, the exact pathogenic mechanism of mutant fused in sarcoma (FUS) protein is not completely understood. FUS is an RNA binding protein (RBP) localized predominantly in the nucleus, but ALS-linked FUS mutations can affect...
Autores principales: | Tejido, Clara, Pakravan, Donya, Bosch, Ludo Van Den |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380926/ https://www.ncbi.nlm.nih.gov/pubmed/34434087 http://dx.doi.org/10.3389/fnmol.2021.686995 |
Ejemplares similares
-
Role and therapeutic potential of liquid–liquid phase separation in amyotrophic lateral sclerosis
por: Pakravan, Donya, et al.
Publicado: (2020) -
Therapeutic potential of HDAC6 in amyotrophic lateral sclerosis
por: Guo, Wenting, et al.
Publicado: (2017) -
Opportunities for histone deacetylase inhibition in amyotrophic lateral sclerosis
por: Klingl, Yvonne E., et al.
Publicado: (2020) -
Human motor units in microfluidic devices are impaired by FUS mutations and improved by HDAC6 inhibition
por: Stoklund Dittlau, Katarina, et al.
Publicado: (2021) -
HDAC6 inhibition reverses axonal transport defects in motor neurons derived from FUS-ALS patients
por: Guo, Wenting, et al.
Publicado: (2017)